The GLP-1 Legacy

Life After Ozempic, Wegovy and Mounjaro

What Happens When The Medication Stops?

Over recent years, GLP-1 medications have transformed the treatment of obesity. For many individuals, they have delivered levels of weight loss and appetite control that were previously difficult to achieve, reducing hunger and turning down the constant focus on food. However, far less attention is given to what happens next.

For many, this is where the real challenge begins. Appetite returns, food becomes more compelling, and maintaining weight loss requires significantly more behavioural effort. The support that made weight loss feel manageable is no longer in place.

When Support Falls Away

GLP-1 treatments such as Mounjaro, Ozempic and Wegovy are intended to be combined with behavioural and lifestyle input alongside the medication. In practice, however, that level of structured guidance is often limited or, in some cases, almost non-existent.

Many users are left to navigate the transition off the medication with very little assistance, often turning to the internet for answers. This is reflected in the tens of thousands of daily searches on the topic. It was this consistent pattern, observed both clinically and in wider public behaviour, that led to the research and writing of The GLP-1 Legacy.

About The GLP-1 Legacy

The GLP-1 Legacy was written to support users both during and after GLP-1 treatment, particularly as medication is reduced or stopped and more responsibility begins to shift back to the individual. Drawing on more than 15,000 hours of experience in behavioural weight management, Martin and Marion Shirran explore the patterns, habits and psychological factors that influence how weight loss can be sustained once the medication is no longer doing the heavy lifting.

Whether read during GLP-1 treatment or after it has stopped, the book focuses on helping changes become more sustainable. While appetite is reduced and food thoughts are quieter, it creates a window where those changes are easier to put in place. As one reviewer noted, they wished they had read it earlier, when far less effort would have been required.

What the Book Explores

From our work with people using GLP-1s and the broader conversations around it, the same questions come up repeatedly:

• How do I maintain this weight loss?
• Is it actually possible to keep it off?
• What happens when my appetite returns?
• How long do the effects of the medication last after stopping?
• Why does weight regain happen, even when I’m trying?
• What habits really make a difference long term?

It also introduces emerging approaches such as tapering and microdosing strategies, helping readers think more carefully about how they transition away from medication, rather than stopping abruptly without a plan. The book explores the interaction among biology, behaviour and the environment, and outlines practical approaches to sustaining progress.

Clinical Perspective

The book includes a foreword by Professor Jane Ogden, Professor of Health Psychology at the University of Surrey, whose work has significantly contributed to the understanding of eating behaviour and long-term weight management. Her involvement provides an academic perspective on the behavioural challenges associated with weight maintenance after GLP-1 treatment.

Why Maintenance Matters

GLP-1 medications are proving highly effective for supporting weight loss. However, they do not in themselves establish the habits, routines or cognitive patterns required for long-term maintenance. When medication is reduced or withdrawn, appetite returns and the behavioural drivers that influenced eating before treatment often reappear. Without preparation, many former users find themselves managing the same challenges as before, but now without the support of the medication. This is where weight regain most often begins.

Understanding and preparing for this post-GLP-1 phase is central to maintaining outcomes and protecting the progress that has already been achieved. The pages on this website provide an overview of The GLP-1 Legacy, including a detailed introduction to the authors and an expanded synopsis.

For clinicians working within limited consultation time, the book provides a practical resource that patients can use independently, both during their weight-loss journey and as they transition off the medication. It is increasingly being recommended by healthcare professionals as a way to support patients beyond prescribing, particularly at the point where behavioural strategies become critical to maintaining results.

Intended Audience

This site and the book are intended for:

• individuals who are using or have used GLP-1 medications and wish to maintain their weight loss
• healthcare professionals seeking a behaviourally informed resource to support patients during and after treatment

FDA

In the United States, the Food and Drug Administration (FDA) has mandated that GLP-1 receptor agonist weight-loss medications be prescribed in conjunction with a behavioural change programme. The FDA’s approach aims to ensure that patients not only lose weight but also adopt healthier lifestyle habits, which is crucial for maintaining their weight loss in the long term. This regulatory stance underscores the necessity of a comprehensive treatment plan, as detailed on the pages of this website.

NICE

Similarly, the National Institute for Health and Care Excellence (NICE) in the United Kingdom advocates a multifaceted approach to weight management. NICE recommends that weight-loss medications be integrated into a comprehensive weight management programme. The Guidance from Nice emphasises the importance of addressing obesity through a holistic and sustainable approach, aiming to deliver long-term health benefits and improved quality of life for patients. Marion Shirran, the co-founder of Oxford Therapeutics Ltd and the co-author of The GLP-1 Legacy, is a NICE stakeholder and a member of the All-Party Parliamentary Group on Obesity.